Dasatinib (DST)
Dasatinib is a cancer drug produced by Bristol-Myers Squibb and sold under the trade name Sprycel. Dasatinib is an oral multi- BCR/Abl and Src family tyrosine kinase inhibitor approved for first line use in patients with chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It is being evaluated for use in numerous other cancers, including advanced prostate cancer.dasatinib was tested in patients who were resistant to or who could not tolerate imatinib. Complete hematological responses were seen in 37 of 40 patients with chronic-phase CML. Major hematologic responses were seen in 31 of 44 patients with accelerated-phase CML, CML in blast crisis, or Ph+ ALL. The main targets of dasatinib are BCR/Abl, Src, c-Kit, ephrin receptors, and several other tyrosine kinases, but not erbB kinases such as EGFR or Her2.

Organism species: Pan-species (General)

CATALOG NO. PRODUCT NAME APPLICATIONS
Proteins n/a Complete Antigen of Dasatinib (DST) Antigenic Transformation Customized Service Offer
Antibodies n/a Monoclonal Antibody to Dasatinib (DST) Monoclonal Antibody Customized Service Offer
n/a Polyclonal Antibody to Dasatinib (DST) Polyclonal Antibody Customized Service Offer
Assay Kits n/a CLIA Kit for Dasatinib (DST) CLIA Kit Customized Service Offer
n/a ELISA Kit for Dasatinib (DST) ELISA Kit Customized Service Offer